Nyxoah's ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints
Benzinga Newsdesk 2 months ago
BiotechGeneralNews
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse PatientsReports an Apnea-Hypopnea Index (AHI) responder rate of 77.2% on a Full Analysis Set basis
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
Reports an Apnea-Hypopnea Index (AHI) responder rate of 77.2% on a Full Analysis Set basis (p<0.001)
Zero device-related serious adverse events through 12 months